A recent pilot study carried out by Macfarlane et At 0, 12, and 24 weeks a full blood count, platelets, and ESR were checked, while rheumatoid factor and antinuclear antibody were measured at 0 and 24 weeks. All patients were reviewed by the same metrologist at 0, 6, 12, and 24 weeks, who recorded pain using a 10 cm visual analogue scale, duration of morning stiffness, Ritchie articular index,5 and grip strength. The treatment given to any particular patient was not indicated to the metrologist.
All patients gave informed consent before entry into the study and were able to change to alternative 667 Rheumatoid factor measurements were carried out in two laboratories using a Rose-Waaler and an enzyme linked immunosorbent assay (ELISA) technique. Using the Rose-Waaler method in the phenytoin patients (n= 12) the median rheumatoid factor remained static from week 0 to week 24, whereas in the gold patients (n= 12) the median rheumatoid factor changed from 1/256 to 1/32 (p=0-012; Wilcoxon matched pairs signed ranks test). Similarly, the median rheumatoid factor measured by the ELISA technique in the phenytoin patients (n=9) changed from 8800 to 5600 units/ml (not significant), whereas in the gold group (n=9) the change was from 4650 to 1800 units/ml (p<0-02; Wilcoxon matched pairs signed ranks test).
There was a wide range of phenytoin levels at week 24 (14-90 ,umol/l). We therefore compared the degree of change in clinical and laboratory parameters in those patients with a level less than the median value at week 24 (42 [tmol/l) with those who attained a level greater than the median. There was no significant difference between the groups.
Discussion
This study was designed to assess the place of phenytoin as a second line agent in rheumatoid arthritis. No unexpected toxicity was encountered with either gold or phenytoin. We arbitrarily chose a therapeutic level consistent with that used in patients treated with phenytoin for seizures. These levels were satisfactorily achieved at weeks 12 and 24 in most cases.
The expected clinical and laboratory response was seen in the gold treatment group. There was, however, no evidence of a second line effect in the phenytoin group in terms of symptom control, though significant changes were shown in the Ritchie articular index after 24 weeks' treatment. 
Nevertheless, there did appear to be a laboratory response to phenytoin in that the haemoglobin rose and the ESR and platelets fell.
The discordant clinical and laboratory effects of phenytoin are difficult to explain. It 
